A big development for cannabis and CBD research came on July 23rd; Harvard University researchers from the Dana-Farber Cancer Institute released their results from a study conducted on cannabis' effects on pancreatic cancer. Their conclusion was that a chemical in cannabis could have a "major impact" in treatment therapies for the cancer. This news is an important addition to the ever-growing ways that CBD is showing promise in being a vital health component.
The result of this study are heartening; Five-year survival rates for pancreatic are less than eight percent. While pancreatic cancer makes up only three percent of cancer diagnoses currently, by 2020 it's predicted to increase and be the second highest cause of cancer-related deaths.
So, just what chemical was it that the scientists found promising in treatment therapies? It's a flavonoidcalled "FBL-03G". Flavonoids are found throughout the natural world in plants, fruits, and vegetables and are responsible for their coloring; They are also thought to provide many different health benefits. Only .14 percent of cannabis plants are comprised of flavonoids, but they're thought to have a large impact on establishing how the plant interacts with and effects the human body.
When researchers decided to take the FLB-038 flavonoid from cannabis and test its effects on pancreatic cancer, they described the results as "major". When one of the researchers, assistant professor Wilfred Ngwa, PHD, spoke to Yahoo Lifestyle he stated the following of the results:
"The most significant conclusion is that tumor-targeted delivery of flavonoids, derived from cannabis, enabled both local and metastatic tumor cell kill, significantly increasing survival from pancreatic cancer. This has major significance, given that pancreatic cancer is particularly refractory to current therapies.”
Ngwa went on to explain that they believe the cannabis flavonoid is working directly with the immune system; This is because it not only attacked the pancreatic cancer cells, but attacked other cancer cell types as well.
Researchers are hopeful that this development could open doors for increasing life expectancy after diagnosis. More study is needed, but the Harvard researchers are now planning to conduct clinical studies. The studies are expected to be completed in 2020. Hopefully, we'll see some further positive development at that time.